Key Points
- William Carson, an Annexon director, purchased 4,115 shares on Dec. 30 at an average price of $5.02 (≈$20,657), increasing his stake to 54,405 shares—a rise of 8.18%.
- Annexon stock opened at $4.69, trades in a 52‑week range of $1.28–$5.66, and the company remains loss-making (last quarter EPS -$0.37; FY consensus -$0.96) with 50‑day/200‑day moving averages of $4.16/$3.14.
- Analysts are mixed but skew positive: the consensus rating is Moderate Buy with a $17 consensus price target, while Wells Fargo raised its target to $27 and Chardan initiated coverage with a $16 target.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William Carson purchased 4,115 shares of the business's stock in a transaction that occurred on Tuesday, December 30th. The stock was bought at an average price of $5.02 per share, with a total value of $20,657.30. Following the completion of the purchase, the director owned 54,405 shares of the company's stock, valued at $273,113.10. This trade represents a 8.18% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Annexon Stock Performance
Shares of NASDAQ ANNX opened at $4.69 on Friday. The stock has a market capitalization of $561.08 million, a P/E ratio of -3.33 and a beta of 1.20. Annexon, Inc. has a 52 week low of $1.28 and a 52 week high of $5.66. The stock's fifty day moving average is $4.16 and its 200 day moving average is $3.14.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Equities research analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on ANNX. Chardan Capital started coverage on shares of Annexon in a research note on Tuesday, December 23rd. They issued a "buy" rating and a $16.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Annexon in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company increased their price objective on shares of Annexon from $14.00 to $27.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 19th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.
View Our Latest Research Report on ANNX
Institutional Trading of Annexon
Hedge funds and other institutional investors have recently bought and sold shares of the business. Citizens Financial Group Inc. RI increased its position in shares of Annexon by 14.3% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company's stock worth $122,000 after acquiring an additional 5,000 shares in the last quarter. CWM LLC increased its position in shares of Annexon by 32.4% during the 3rd quarter. CWM LLC now owns 23,488 shares of the company's stock valued at $72,000 after purchasing an additional 5,754 shares during the last quarter. Hsbc Holdings PLC raised its position in Annexon by 19.9% in the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock worth $73,000 after acquiring an additional 6,136 shares during the period. Comerica Bank raised its holdings in shares of Annexon by 26.4% in the 3rd quarter. Comerica Bank now owns 32,357 shares of the company's stock worth $99,000 after purchasing an additional 6,750 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock valued at $193,000 after buying an additional 7,553 shares during the last quarter.
About Annexon
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
